DK4076461T3 - Lumateperon til brug ved behandling af skizofreni - Google Patents

Lumateperon til brug ved behandling af skizofreni

Info

Publication number
DK4076461T3
DK4076461T3 DK20900863.0T DK20900863T DK4076461T3 DK 4076461 T3 DK4076461 T3 DK 4076461T3 DK 20900863 T DK20900863 T DK 20900863T DK 4076461 T3 DK4076461 T3 DK 4076461T3
Authority
DK
Denmark
Prior art keywords
lumateperone
schizophrenia
treatment
Prior art date
Application number
DK20900863.0T
Other languages
Danish (da)
English (en)
Inventor
Robert E Davis
Kimberly Vanover
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Application granted granted Critical
Publication of DK4076461T3 publication Critical patent/DK4076461T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20900863.0T 2019-12-19 2020-12-18 Lumateperon til brug ved behandling af skizofreni DK4076461T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950828P 2019-12-19 2019-12-19
PCT/US2020/066224 WO2021127572A1 (en) 2019-12-19 2020-12-18 Methods of schizophrenia treatment

Publications (1)

Publication Number Publication Date
DK4076461T3 true DK4076461T3 (da) 2026-02-23

Family

ID=76437353

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20900863.0T DK4076461T3 (da) 2019-12-19 2020-12-18 Lumateperon til brug ved behandling af skizofreni

Country Status (14)

Country Link
US (1) US20210186962A1 (enExample)
EP (2) EP4744678A3 (enExample)
JP (2) JP7727634B2 (enExample)
DK (1) DK4076461T3 (enExample)
ES (1) ES3067760T3 (enExample)
FI (1) FI4076461T3 (enExample)
HR (1) HRP20260406T1 (enExample)
LT (1) LT4076461T (enExample)
PL (1) PL4076461T3 (enExample)
PT (1) PT4076461T (enExample)
RS (1) RS67890B1 (enExample)
SI (1) SI4076461T1 (enExample)
SM (1) SMT202600134T1 (enExample)
WO (1) WO2021127572A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
IL297333B2 (en) * 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
CA2719824A1 (en) * 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
KR102967223B1 (ko) * 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP7013454B2 (ja) * 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
CA3082834A1 (en) * 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
WO2019102240A1 (en) * 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) * 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof

Also Published As

Publication number Publication date
EP4076461A4 (en) 2024-01-03
EP4744678A2 (en) 2026-05-20
JP7727634B2 (ja) 2025-08-21
JP2025166121A (ja) 2025-11-05
HRP20260406T1 (hr) 2026-05-08
JP2023507584A (ja) 2023-02-24
LT4076461T (lt) 2026-06-25
EP4744678A3 (en) 2026-07-22
WO2021127572A1 (en) 2021-06-24
EP4076461B1 (en) 2026-01-28
PL4076461T3 (pl) 2026-04-27
SI4076461T1 (sl) 2026-05-29
EP4076461A1 (en) 2022-10-26
US20210186962A1 (en) 2021-06-24
RS67890B1 (sr) 2026-04-30
PT4076461T (pt) 2026-04-16
FI4076461T3 (fi) 2026-03-24
SMT202600134T1 (it) 2026-05-12
ES3067760T3 (en) 2026-05-25

Similar Documents

Publication Publication Date Title
HUS2500039I1 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK4010329T3 (da) Deutererede forbindelser til anvendelse ved behandling af cancer
DK4327866T3 (da) Mirikizumab ved behandling af ulcerøs kolitis
DK3364997T5 (da) Aspartoacylase genterapi til behandling af canavans sygdom
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
DK3496739T3 (da) Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
DK3970707T3 (da) Anvendelse af cannabidivarin i behandling af negative symptomer ved skizofreni
HRP20260406T1 (hr) Lumateperon za primjenu u liječenju shizofrenije
DK3497095T3 (da) Zinkchelaterende forbindelser til anvendelse ved behandlingen af bakteriel infektion
EP3352863A4 (en) Molybdenum disulfide and related materials for water treatment
EP3434291A4 (en) COMPOSITION FOR THE TREATMENT OF BELTS
DK3551189T3 (da) Alprazolam til anvendelse ved behandling af epilepsi
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3556383T5 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3522904T3 (da) Flydende sammensætning til anvendelse i behandlingen af gastroesophageal reflux
DK3344655T3 (da) Brug af anti-cd40-antistoffer til behandling af lupus nefritis
EP3484854A4 (en) APOPTOSIS INHIBITORS
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies